Document:

Exhibit 4.11

 

 

 

CERTAIN
CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE
THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

 

Appendix No. 2 (“Appendix”)

 

Date:   02 February 2021

 

 

 

Parties

 

		1.	Novotech (Australia) Pty Limited ACN 071 874 881 of Level
3, 235 Pyrmont Street, Pyrmont, NSW 2009, Australia (Novotech)

 

		2.	Incannex Healthcare Ltd, ABN 33 630 326 902 of Unit 207,
11 Solent Circuit, Norwest, 2153, New South Wales, Australia (Sponsor)

 

 

 

Background

 

		A	On 25-Jun-2020, Clinical Network Services (CNS) Pty Limited
(CNS) and Sponsor entered into a Master Consultancy Agreement (MCA) pursuant to which CNS will provide clinical management,
data management, biostatistical, medical monitoring, medical writing, pharmacovigilance, quality assurance, regulatory, site management
organisation, central laboratory and other related services to support clinical trials to Sponsor.

 

		B	Novotech is an Affiliate (as defined in the MCA) of CNS and
the parties mutually agree that Novotech shall provide the Services to Sponsor.

 

		C	The parties further agree that all services performed by Novotech
pursuant to this Appendix shall be governed by the terms and conditions set forth in the MCA. Specifically, Novotech shall be subject
to all of the obligations applicable to CNS under the MCA. For purposes of this Appendix, all references to CNS under the MCA are hereby
deemed references to Novotech and Novotech agrees to be legally bound by all of the obligations contained therein.

 

		D	The parties further agree that all references to MSA throughout
this Appendix refer to the MCA.

 

		E	The parties agree that this Appendix sets out the services that
Sponsor requests Novotech, and Novotech agrees, to provide under the terms of the MSA for the following study: An Open Label Extension
on the Examination of the Combination of Dronabinol and Acetazolamide for Treatment of Obstructive Sleep Apnoea (OSA); IHLOSAOLE1(Study).

 

		F	This agreement commences on the date the last Party signs the
Appendix.

 

The Parties hereby agree as follows:

 

 

 

		1	Key Assumptions

 

		1.1	The Budget for the Services (which includes the Fee and estimated
pass through costs and is attached at Schedule 1) is derived from the Study Assumptions and Responsibilities (together, Key Assumptions)
set out below.

 

		1.2	The parties agree that the Key Assumptions accurately reflect
the Study parameters and the Services to be performed by Novotech.

 

		1.3	If there are changes to the Key Assumptions or additional tasks
are required to provide the Services, Novotech will amend the Budget to reflect those changes and the parties agree to vary this Appendix
to include those changes.

 

		1.4	Sponsor agrees that time is of the essence for the Study and
will align its objectives and timing for the Study with those of Novotech.

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 1 of 21

     

    

 

STUDY ASSUMPTIONS

 

General

 

		1)	The study will be conducted in strict accordance with the Protocol,
the quality practices as detailed in ICH GCP, and Australian regulations detailed in its document “Integrated Addendum to ICH E6(R1):
Guideline for Good Clinical Practice ICH E6(R2) - Annotated with Therapeutic Goods Administration (TGA) comments as below, 25 June 2018”,
the DIA TMF Reference Model as well as the current Declaration of Helsinki, collectively referred to hereafter as “GCP standards”.

 

		2)	Novotech will archive their own records for a period determined
by GCP standards and/or local Australian regulations as applicable. All other original files and records including a GCP standard electronic
Trial Master File (eTMF) will be returned to Incannex at the conclusion of the study. The TMF will contain completed sections for which
Novotech are directly responsible. Vendors and sites that are not managed by Novotech may not be included unless otherwise agreed upon
by Incannex and Novotech.

 

		3)	Novotech will utilise SureClinical as the cloud-based eTMF for
this study, as they are FDA Part 11 and European Commission Annex 11 compliant. SureClinical will enable Incannex to securely acquire,
view, share and manage clinical trial electronic content in the trial master files including those from other vendors, as well as, those
related to the site. SureClinical ensures that study documents, medical images and eRecords are always available to all stakeholders,
even when offline. Novotech will be responsible for ensuring that the Investigator and/or study coordinator maintains and updates the
regulatory files at the site. At each interim monitoring visit and close-out visit the site file will be reviewed for consistency with
the eTMF maintained by Novotech.

 

		4)	Novotech will ensure all required documents and records are
included in the TMF throughout the study and will provide a final review for completeness at the conclusion of the study. The complete
TMF, inclusive of final CRF data and statistical outputs on digital media is the final deliverable in this project.

 

		5)	Novotech uses Oracle Siebel® Clinical Trial Management
System (CTMS) and can either provide direct access for Incannex to the reports module of this system, or forward reports to your team
for review on a regular basis (e.g. along with the agenda of the regular team calls).Oracle Siebel® provides visibility
and access to: site start up status, site contracts and budgets, ethics committee submissions and approvals, patient enrolment, monitoring
visit reports, frequently asked questions, protocol deviations, accessible reports that can be sent to Incannex weekly and ad hoc and
tracks timelines and key project deliverables.

 

Lead-In and Operational Project Kick-off

 

		6)	Novotech will appropriately resource the Project Team according
to services required, led by a PM. Upon contract award, the Novotech PM will immediately arrange a kick-off call with Incannex’s
PM to review the scope and timelines and identify any areas for clarification.

 

		7)	Clinical and Biometrics activities will need to commence once
the contract is signed and therefore an operationally focussed project kick-off meeting will be held with all relevant members of the
Project Team and Incannex. At this meeting, the Novotech PM will lead discussion to provide all team members with an understanding of
the trial aims, timelines and expectations of all deliverables to Incannex.

 

		8)	The Project Team will include a Clinical Research Associate
(CRA), Data Manager, Biostatistician, Medical Writer, Medical Monitor and a Project Administrator (PA).

 

		9)	Project Team members will review and familiarise themselves
with the relevant project materials as soon as required duties dictate. The PM will manage interaction of the required Project Team members
with Incannex throughout the project.

 

Investigator Brochure (IB) Development

 

		10)	Incannex will provide Novotech with an ICH-GCP compliant Investigator’s
Brochure.

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 2 of 21

     

    

 

Protocol Development

 

		11)	Incannex will provide Novotech with an ICH-GCP compliant Study
Protocol.

 

Site Identification and
Selection

 

		12)	Incannex can identified the site to perform the proposed study.
It is assumed that Incannex have performed appropriate assessments of the site’s suitability and capabilities to conduct this study.
Whilst not included in this Appendix, Novotech can perform a Site Selection Visit (SSV) upon request.

 

Clinical Services

 

		13)	Following confirmation of the site and finalisation of the protocol,
Novotech initiate Data Management activities (See below).

 

		14)	Incannex will assist the site with preparation of submission
packages to their Human Research Ethics Committee (HREC) including the development and approval of compliant PIC/F and any other patient
materials, including all patient assessment materials, advertising etc. It is assumed that a diary card is not applicable to this study
but should one be utilised, Incannex will advise Novotech so suitable solutions may be discussed and added to future iterations of this
Appendix.

 

		15)	Incannex will co-ordinate and manage the Clinical Trial Research
Agreement (CTRA) with the site including payments to the site.

 

		16)	An Investigator Meeting is not considered necessary for this
study and is not included in this Appendix.

 

		17)	Novotech will collect necessary regulatory documents and will
establish and maintain applicable filing systems in compliance with GCP standards.

 

		18)	Following receipt of HREC approval and acknowledgement of the
clinical trial notification (CTN) from the TGA, Novotech will perform a Site Initiation Visit (SIV) to prepare for commencement of the
study and will review final logistical considerations, Investigational Product (IP), Protocol, CRF training, SAE reporting and GCP training.
Novotech PM may accompany the CRA for this visit to ensure all final logistical matters are reviewed, however, these costs are not included
in the Appendixat this time.

 

		19)	A total of nine (9) days monitoring has been calculated as required
to monitor / source data verify (SDV) 100% subject CRFs against 100% of data points as well as an appropriate regime to ensure timely
review of data, minimisation of data cleaning bottlenecks and identify issues/resolution during the study.

 

		a.	Three (3) 3-day monitoring visits as per the Project Management
Plan

 

		b.	This plan would result in three (3) monitoring visit reports
being generated

 

		c.	The final monitoring visit schedule will be agreed with Incannex
and documented in the study Project Management Plan.

 

		20)	At every visit, the Novotech CRA will perform the following
tasks:

 

		d.	Meet with key site staff to discuss the progress of the study;

 

		e.	Identify any unreported SAEs and implement appropriate reporting
tasks;

 

		f.	Assess study conduct and data recording compliance against the
current approved protocol and log all protocol deviations;

 

		g.	Review CRF data against Source Data for 100% of data points and informed consent for 100% of Participants;

 

		h.	Screen failures will not be reviewed other than consent and reason for failure;

 

		i.	Review IP storage and accountability

 

		j.	Ensure currency of Investigator oversight of
                                                                                                                                                                                                                     the study, site contracted vendors and site study team

 

		k.	Review the Investigator Site File for completeness and collect any updated documents, and;

 

		l.	Document and seek corrective action for all discrepancies and findings.

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 3 of 21

     

    

 

		21)	Novotech will perform a study closure site visit of 1-day (8
hour) duration upon advice from Data Management that the study database is locked. This ensures completion of all GCP standard required
activities and archiving of associated documentation.

 

		22)	Novotech will prepare a visit report, and following internal
review, each final report will be submitted to Incannex within fifteen (15) working days of the last day of site visit.

 

		23)	Any visits of any type required in addition to this will be
charged on a “fee for service” basis following written approval from Incannex.

 

		24)	Novotech will perform in-house site management activities as
required throughout the study, including:

 

		a.	Tracking screening and enrolment

 

		b.	eCRF completion guidance

 

		c.	Resolution of eData Queries

 

		d.	CTMS management

 

		e.	eTMF Maintenance

 

Regulatory

 

		25)	Incannex will act as the local Sponsor in Australia for the
active period of the study. As local Sponsor Incannex will act as required under regulatory authority rules of the TGA and will be responsible
for the following:

 

		a.	Review of product labelling to ensure local compliance of all inner and outer product packaging.

 

		b.	Incannex will maintain suitable study insurance compliant with country requirements and will have Novotech
as additionally insured.

 

		c.	Complete/sign necessary regulatory submission documents.

 

		d.	Complete/sign and maintain study indemnification.

 

		e.	Report any SAEs that are determined to be unexpected and related to the IP (or comparators), termed
SUSARs, to the local regulatory authority.

 

		26)	In Australia, the protocol will be submitted for regulatory
acknowledgement only via the Australian CTN scheme.

 

		27)	Novotech SOPs will be used in the conduct of all activities performed by Novotech
unless otherwise requested by Incannex and following training of applicable Novotech staff by Incannex on Incannex SOPs. The Novotech
PM will ensure currency of training in applicable SOPs is maintained throughout the project.

 

		28)	Incannex will be responsible for registering the study on a Clinical Trial Register
in accordance with local regulations.

 

		29)	Novotech will monitor investigators responsibilities for the Periodic Safety and
Annual Reporting requirements to their applicable HREC and will support the site in their preparations in meeting such requirements. Novotech
will obtain relevant Safety Information from Incannex in order to comply with HREC and Regulatory Authority requirements for ongoing and
study completion advice.

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 4 of 21

     

    

 

Safety Laboratory

 

		30)	It is assumed the site will contract and manage their preferred pathology laboratory
to provide safety pathology testing required per protocol. The site’s PI will be responsible for their preferred laboratory, which
in turn will be responsible for appropriate sample labelling according to local practices.

 

		31)	Novotech will review accreditation of the preferred laboratory during study start
up, collect relevant accreditation and normal range documentation during the essential document collection process after site selection,
confirming correct filing in the TMF and Investigator Site File at the SIV.

 

		32)	Novotech will check to ensure currency of all laboratory documentation during monitoring
visits and collect updated documents as available.

 

		33)	Novotech will review laboratory samples handling and co-ordination throughout the study.

 

		34)	Novotech Data Manager will establish a Laboratory Data Transfer Agreement (LDTA)
with the responsible laboratory for transfer and upload of the safety lab data into Novotech systems. Following a test run, data will
be transferred to Novotech as per the agreed frequency in the LDTA considering protocol specific requirements including dose escalation
data package compilation and data review requirements.

 

		35)	Upon request, Novotech can be responsible for the sourcing, contracting and management of the safety
laboratory. Updated scope and costs will be provided in further versions of this Appendix.

 

Bioanalytical

 

		36)	A bioanalytical lab will not be required for this study.

 

Investigational Product (IP) Management

 

		37)	Incannex will be fully responsible for the packaging and labelling of IMP.

 

		38)	Novotech will prepare a Pharmacy Manual and Novotech will perform local review and make comment as necessary.

 

		39)	Incannex will manage shipment of IP directly to the site.

 

		40)	Novotech will assist in the co-ordination of return of used/unused IP to Incannex per Incannex’s
requirements.

 

Pharmacovigilance

 

		41)	Novotech will utilise Pharmacovigilance (PV) services, utilising Oracle Argus for the safety management
of this study.

 

		42)	The following PV services will be provided:

 

		a.	Set-up and start-up a safety database

 

		b.	Protocol and IB review

 

		c.	SAE Management (ex. Safety Narratives) – Initial

 

		d.	SAE Management (ex. Safety Narratives) – Follow Up

 

		e.	Safety Narratives for Non-expedited Report

 

		f.	SUSAR Management (Includes Narratives/CIOMS Generation)

 

		g.	SUSAR Reporting (Investigator Submission)

 

		h.	Prepare 6 Monthly Line Listing

 

		i.	DSUR Preparation

 

		j.	Generate Monthly Safety Status Report

 

		k.	Safety Management each month

 

		l.	CRA Training

 

		m.	Safety Management Plan

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 5 of 21

     

    

 

		43)	It is assumed that one of subject will experience SAEs during
the study. Novotech will work with the site, MM and Incannex to ensure that all SAEs are reported and followed up correctly.

 

		44)	As local Sponsor, Novotech will be responsible for preparing
CIOMS report and/or submitting reportable SUSARs to the local Investigator for local reporting and to the regulatory authority.

 

Safety Management

 

		45)	A Safety Monitoring Committee (SMC) is not considered necessary for this study.

 

Medical Monitoring

 

		46)	Novotech be responsible for local Medical Monitoring (MM) via a qualified, experienced
medically licensed Doctor. Novotech MM will join the initial team kick-off meeting with the PM and Incannex team to confirm service expectations
and timeline

 

		47)	The MM will be available 24/7 over the period of participant recruitment, treatment
and follow up for medical support of the study inclusive of medical review of;

 

		a.	Inclusion/exclusion queries from
site

 

		b.	Planned protocol deviations

 

		c.	Safety issues arising in the study

 

		d.	SAE reports and related narrative preparation, as required

 

		e.	The final study safety database

 

		48)	After protocol finalisation and prior to the first SIV, a MM Kick Off Meeting
will be arranged between the Novotech MM and Incannex Medical Officer to confirm expectations of the local MM support required throughout
the study. At this meeting a schedule of further meetings, status reports or other contact requirements will be agreed. Thereafter, the
MM and Incannex Medical Officer will maintain contact as required for management of any safety matters as they arise in the study.

 

		49)	During the study start-up, the MM will be given access and training to the study
databases EDC and Laboratory to ensure the MM can provide review of all safety data in real time and with available context data for the
subjects.

 

		50)	The Novotech MM will perform a review of medical coded terms during the study.
The MM can provide a final medical coding review on behalf of Incannex prior to database lock if requested; however, this has not been
included at this time.

 

		51)	MM time has been costed as follows:

 

		●	Unit cost for familiarisation, Kick Off Meeting, protocol review and CSR review/input.

 

		●	A fixed retainer of five (5) hours each month during the 24/7 availability periods of the study. If
greater than 5 hours is required in a given month, NOVOTECH will bill hours as incurred (Timesheet costs) with the agreement of Incannex.

 

		●	Hours as incurred each month during the 24/7 availability periods of the study.

 

Project Management

 

		52)	Overall project management will be provided by Novotech PM noting that as InCannex
will be responsible for start-up activities related to site selection, HREC approvals and CTN submissions, initial Novotech PM role will
be limited to regular communication and development of the eCRF and other Biometrics functions.

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 6 of 21

     

    

 

		53)	Novotech’s PM will maintain regular communications with Incannex as required
by telephone and email. Key activities performed by the Novotech PM include:

 

		a.	Review and management of Novotech budget and project resourcing.

 

		b.	Adherence to Project Timelines.

 

		c.	Provide overall Project Team leadership and liaise with Incannex Project Team on
a regular basis.

 

		d.	Ensure frequent and effective communication within the Novotech Project Team,
with Incannex Project Team and with the site.

 

		e.	Participation in all teleconferences with Incannex and lead internal meetings
throughout the course of the project.

 

		f.	Maintain written documentation of all project correspondence including regular sponsor
meetings.

 

		g.	Collate and review IP Release Packages.

 

		h.	Develop the overall Project Management Plan, Review of Pharmacy Manual. Novotech
assumes that Incannex will review and comment on final version of each and have costed for one round of review only. Project specific
documents are developed as an adjunct to Novotech SOP’s.

 

		i.	Manage prompt resolution of identified problems with appropriate team members,
including timely issue escalation to Incannex. PM will identify potential problems/issues and provide Incannex with recommended solutions
on a proactive basis.

 

		j.	Identification of areas of project risk, mitigation and escalation as required
in conjunction with the project team.

 

		k.	Ensure that proper SOPs are followed and that trial documentation is consistent,
complete, and correct.

 

		l.	Provide review of all key documents/deliverables in the trial for e.g. the eCRF,
Data Management Plan, Randomisation Plan, Statistical Analysis Plan and CSR.

 

		m.	Training of new Novotech staff and ongoing training for Novotech team where contracted.

 

		54)	Teleconferences will be held between Incannex and Novotech Project Team. Teleconferences
are estimated to be of one-hour duration and held weekly throughout the study. Agenda and minutes will be prepared by Novotech PM and
circulated.

 

		55)	Additional meetings may be requested by Incannex either face to face or by telephone.
These meetings will be invoiced at timesheet costs (hours as incurred) for required attendees with prior approval of Incannex.

 

		56)	Formal status reports may also be provided upon request but are not included in
this Appendices it is anticipated that regular teleconferences and other communication will suffice

 

DATA MANAGEMENT

 

		57)	It has been assumed Medidata Rave will be the EDC platform for this study.

 

		58)	Data Management will be provided by Novotech’s Data Management team based
in Australia. Novotech Data Manager will join the initial team kick-off meeting with the PM and Incannex team to confirm service expectations
and timelines. In addition, the Data Manager will work with the PM and Incannex team to clarify Incannex’s requirements in terms
of CRF/Database specifications and expectations with respect to Incannex team’s involvement in the Data Management process.

 

		59)	It has been assumed that a subject diary is not required. However, should one be
required, Novotech can support ePRO/eDiary allows for the safe and secure collection of patient reported outcomes and Electronic Clinical
outcome assessments (eCOA) data directly from patients through multiple platforms using handheld devices such as tablets, smart phones
etc. This service is not included in this Appendix but may be included upon request.

 

		60)	For studies with a substantial number of sites and patients, online randomisation
and trial supply management is a serious option that needs to be considered, i.e. the benefits may outweigh your direct and indirect costs,
and risks. For studies with a few sites and low number of patients, manual randomisation and supply management usually is more cost effective
at acceptable risk.

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 7 of 21

     

    

 

		61)	Novotech deploys a library of CRF pages with
                                                                                                                                                                                                                    variables (questions) and code lists (optional answers) being compliant with CDASH
(CDISC) conventions including variables and code lists required or expected by regulators like the FDA. The regulatory requirements concerning
variables and code lists that need to be collected influence the number of unique pages and edit checks. Novotech strongly recommends
using these CDASH compliant CRF pages unchanged as SDTM compliant datasets will need to be submitted to the regulators.

 

		62)	eCRF/DB costs are based on Novotech using its library of CDASH compliant CRFs for
assessments except for those assessments that are unique to the protocol and not in the CRF library. Deviating from the standard CRFs
might incur costs. At the time of this Appendix, Novotech has assumed 200 CRF pages and 400 edit checks. These estimates will be updated
upon finalisation of the protocol.

 

		63)	Incannex will be involved in reviewing the CRF/Database; following a CRF screen
review session with client the database will be updated and the annotated CRF presented to Incannex for sign off thus confirming the specifications
of the CRF/Database. Further changes after client sign-off of the annotated CRF will incur costs for implementing and testing the additional
changes. If so, a new annotated CRF will be presented for sign-off to client prior to Go Live of the CRF/Database.

 

		64)	A Data Management Plan (DMP) will be developed in compliance will Good Data Management
Practices (GDMP), updated as required and forwarded to Incannex for review. This document will determine all Data Management activities.
In addition, a Data Review Plan will be developed addressing data consistency checks that cannot be addressed via edit checks.

 

		65)	Novotech will work closely with Medidata Rave and the site in the design of an electronic,
online CRF/Database (eCRF/DB), inclusive of edit checks.

 

		66)	User Acceptance Testing (UAT) will be undertaken of the final draft eCRF in order
to test and confirm expected performance of the system prior to finalisation and being released as final. Any issues found will be rectified
prior to eCRF release. There will be no additional charges for required/requested additional screens or checks prior to launch of eCRF
(release for use).

 

		67)	This database will be maintained by Novotech until the PM confirms that the database
can be decommissioned after submission of the second version of the tables, figures and listings (TFLs), unless agreed otherwise.

 

		68)	Prior to or around the SIV, all users of the eCRF at the site, at Novotech and,
if desired, at Incannex will need to have completed their training in the use of the eCRF system. Novotech also provide eCRF Completion
Guidelines for use at the site.

 

		69)	Following training, user accounts will be activated for the users at the site,
the Novotech clinical team, and if desired for Incannex. Over the course of the study, all eCRF users (site and clinical teams) have access
to 24/7 helpdesk support.

 

		70)	All Adverse Events and Medical History medical verbatim terms will be coded using
the Medical Dictionary for Regulatory activities (MedDRA). Incannex will be required to source and hold a (limited) MedDRA licence per
MedDRA licensing requirements. Please note Novotech is unable to oversee MedDRA licencing on behalf of the client due to MedDRA’s
own policy.

 

		71)	Concomitant medications will be coded using WHO Drug Global unless indicated otherwise
by Incannex. Incannex will be required to hold a WHO Drug Global licence per WHO-Drug Global licensing requirements.

 

		72)	Pathology data will be transferred in electronic format directly by the laboratory
to Novotech or if applicable directly entered into the eCRF by site staff. The Electronic Data Transfer process (EDT) of laboratory data
will be described in the LDTA. A separate LDTA will be agreed for each laboratory and each type of laboratory dataset.

 

		73)	Should Incannex determine the need for additional applications and services for
the project, for example, an online randomisation system, trial supply management system, or imaging system, Novotech can support these.
Any additional costs, both professional fees and application services fees, will be provided in further versions of this Appendix.

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 8 of 21

     

    

 

		74)	The costs for review of
                                                                                                                                                                                                                    CRF data and reconciliation of CRF data with third party data (e.g. safety laboratory data, PK data), are based on the available
                                                                                                                                                                                                                    protocol (synopsis) details at the time of contracting and Novotech best practices.
If changes to the scope and nature of data being collected, the visit-event structure, or other changes that impact the data review time,
Novotech will contact Incannex to discuss the cost implications of the budgeted versus the true data review time required.

 

		75)	The cost does not include data exports of the raw data for Incannex’s perusal.

 

		76)	Edit checks will be programmed in the eCRF. These include missing data, ranges,
consistency checks between visits etc. The Data Review Plan will also list all manual queries such as reconciliation of AEs, ConMeds,
checking of protocol deviations, etc.

 

		77)	Once all requirements for hard locking the database have been met, the database will be hard- locked
and data exported for analysis to the Biostatistics team.

 

Biostatistics

 

		78)	Biostatistical support to the study will be provided by Novotech’s Biostatistics
team based in Australia. Novotech Biostatistician will join the initial team kick-off meeting with the PM and Incannex to confirm service
expectations and timelines.

 

		79)	Following the start of study enrolment, the Biostatistician will develop a draft
Statistical Analysis Plan (SAP) to define the statistical analysis as required by the final protocol, which will be sent to Incannex for
review and comment. Incannex will provide consolidated comments to Novotech for incorporation into the final draft.

 

		80)	A final draft version of the SAP will be issued to Incannex for review to ensure
Novotech have correctly incorporated Incannex’s required changes. The SAP will then be finalised immediately prior to any statistical
analysis following database lock. It is expected that only minor changes related to the previous review will be required at this time.
Any major changes or amendments required to the final draft SAP, will be invoiced on a timesheet basis.

 

		81)	The SAP will contain appendices listing the planned TLFs. Shell/mock TLFs will be created as an adjunct
to the SAP and will be sent to Incannex for separate review and approval.

 

		82)	Any additional changes and subsequent reviews to the SAP and/or TLF shells, and/or
any changes to the study that therefore necessitate changes to the SAP and/or TFL shells (e.g. major changes to the protocol after SAP
drafting and/or approval) will be subject to timesheet cost invoicing to Incannex by Novotech.

 

		83)	CDISC Submission Package:

 

		a.	CDISC Conversion – SDTM: Novotech will prepare a CDISC-compliant SDTM data
package that will include: Domain-level SAS® datasets and transport files and the define.mxl file including the supporting annotated
case report form (blankcrf.pdf) and the Study Data Reviewer’s Guide (SDRG), as well as the applicable Pinnacle21 validation reports. The
final SDTM data package will be sent together with the final TLF package.

 

		b.	The SDTM data package will be based on the SDTM Implementation Guide and Coded
Terminology versions decided at the start of the study. If required, the SDTM specifications can be reviewed by the sponsor prior to the
start of programming.

 

		c.	CDISC Mapping – ADaM: Novotech will prepare a CDISC-compliant ADaM data package
that will include: Analysis-level SAS® datasets and transport files and the define.mxl file including the supporting Analysis Data
Reviewer’s Guide (ADRG), as well as the applicable Pinnacle21 validation reports. The final ADaM data package will be sent together with
the final TLF package.

 

The ADaM data package will be based
on the ADaM Implementation Guide and Coded Terminology versions decided at the start of the study. If required, the ADaM specifications
can be reviewed by the sponsor prior to the start of programming.

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 9 of 21

     

    

 

		84)	Novotech will perform eight (8) PD review of the protocol defined parameters namely:

 

		a.	Polysomnography (PSG)

 

		b.	Oxygen desaturation index (ODI)

 

		c.	Epworth Sleepiness Scale

 

		d.	Stanford Sleepiness Scale

 

		e.	POMS-2 (Profile of Moods State),

 

		f.	Short-from 36

 

		g.	Seizure frequency

 

		h.	Actigraphy (using Actiwatch)

 

		85)	All final tabulation and analysis will be conducted using an appropriate, current
and validated statistical software package. Draft TLF’s will be provided to Novotech Medical Writer and Incannex for review. Upon
receipt of Incannex comments, the final TLFs will be prepared, and following necessary review by the Novotech team, final TLFs will be
issued to Incannex for sign off and acceptance. Major changes to the format/layout from the approved TLF shells will be subject to timesheet
cost invoicing to Incannex by Novotech. Additional round of review and/or updates to the TLFs (beyond the 2 provided) will be subject
to timesheet cost invoicing to Incannex by Novotech.

 

		86)	The estimated number of derived datasets (CDISC SDTM and ADaM) and Tables, Listings
and Figures, to be provided by Novotech is as follows:

 

	# CDISC SDTM Datasets	[***]
	# CDISC ADaM Datasets	[***]
	# Unique Tables	[***]
	# Unique Figures	[***]
	# Unique Listings	[***]
	# Repeat Tables	[***]
	# Repeat Listings	[***]
	# Cohorts	[***]
	# Analytes	[***]

 

		87)	At the time of SAP finalisation, the assumptions around number of TFLs will be
reviewed and any changes will be re-costed accordingly.

 

		88)	A formal statistical report will not be produced. Limited, per protocol tabulations/figures
and listings will be prepared per protocol requirements and provided to the Novotech Medical Writer for preparation of the Clinical Study
Report (CSR).

 

Clinical Study Report
(CSR)

 

		89)	Novotech will be responsible for development of the CSR. Novotech Medical Writer
will join the initial team kick-off meeting with the PM and Incannex team to confirm service expectations and timelines.

 

		90)	Novotech will produce the CSR using standardized content templates that comply
with all ICH and regional structure and formatting requirements.

 

		91)	Novotech will develop a shell clinical study report in accordance with protocol
requirements and ICH E3 standards for review by Incannex.

 

		92)	Following finalisation of the TFLs, Novotech will prepare a first draft CSR which
will be sent to Incannex for review, comment and/or approval. Incannex will provide consolidated comments to Novotech for incorporation
into the final draft.

 

		93)	A second draft version of the CSR will then be issued to Incannex for review to
ensure Novotech have correctly incorporated Incannex’s required changes. It is expected that only minor changes related to the previous
review will be required at this time. Any major changes or amendments required to the final draft CSR, may be invoiced on a timesheet
basis.

 

		94)	Novotech will finalise the CSR and following internal QC, the final CSR will be
issued for the site’s PI and Incannex approval and final sign off. Following sign off of the CSR, Novotech will format the CSR.

  

		95)	Any additional changes and subsequent reviews to the CSR and/or any changes that
require changes to the statistical analysis output and by definition changes to the SAP will be subject to timesheet cost invoicing to
Incannex by Novotech.

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 10 of 21

     

    

 

ESTIMATED RPOJECT TIMELINES

 

The following timeline projection
is offered as an educated yet realistic estimate of the study timeline from signing of the contract, through to the return of Trial Master
File. This estimation is highly dependent upon date of sign-off of contract, site availability / clinic dates, EC approval and Subject
recruitment. These timelines do not consider any holiday periods and a final timeline will be provided by the Novotech PM upon contract
award which will reflect any holiday periods and relevant input from the site.

 

	 	Estimated Schedule
	
     

    Activity
	Estimated

 Start Date	Estimated 

End Date	Activity

 Duration

 (Wks)	Cumulative

 Duration 

(Mths)
	Contract	[***]	[***]	[***]	[***]
	Contract Signature	[***]	[***]	[***]	[***]
	Operational Start Up	[***]	[***]	[***]	[***]
	Operations Kick-off Meeting	[***]	[***]	[***]	[***]
	Final Protocol & IB Available	[***]	[***]	[***]
	Start Up & Document Preparations	[***]	[***]	[***]
	Ethics (First Submission to Last Approval)	[***]	[***]	[***]
	
    Regulatory Approval (First Submission
    to

    Last Reg Appr)
	[***]	[***]	[***]
	eCRF Design & Build	[***]	[***]	[***]
	UAT/Training/Go Live	[***]	[***]	[***]
	Site Initiation Visits	[***]	[***]	[***]
	Study Recruitment & Treatment	[***]	[***]	[***]	[***]
	Screening: Day -56 to Day -1 (n=12)	[***]	[***]	[***]	[***]
	V1 to V8: Day 1 to Day 178 (n=12)	[***]	[***]	[***]
	LPLV to Database Lock	[***]	[***]	[***]	[***]
	Last CRF Monitored	[***]	[***]	[***]	[***]
	
    Data Query to Database Lock (Incl
    Blinded

    Review)
	[***]	[***]	[***]
	Study Closure	[***]	[***]	[***]	[***]
	Statistical Analysis to Draft TFLs	[***]	[***]	[***]	 
	Client TFL Review	[***]	[***]	[***]
	Review to final TFL	[***]	[***]	[***]
	Draft CSR	[***]	[***]	[***]
	Client Review of CSR	[***]	[***]	[***]
	Final Draft CSR	[***]	[***]	[***]
	Client Review of Final Draft CSR	[***]	[***]	[***]
	Final CSR For Signature	[***]	[***]	[***]
	Closeout Visits	[***]	[***]	[***]
	Project Closure & Return of Deliverables	[***]	[***]	[***]
	Months	[***]

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 11 of 21

     

    

 

		2	Payment

  

		2.1	Invoices to Sponsor will be sent to:

  

Rosemarie Walsh

PO Box 324, Collins Street West,

Melbourne, VIC 8007

Australia

Tel: [***]

Email: [***]

 

For each Appendix:

 

Professional Fees
and Expenses

 

		(a)	Sponsor will pay Novotech’s Professional Fees and Expenses
in connection with the Services as set out in the Appendix (Professional Fees).

 

		(b)	The Sponsor will pay any and all applicable taxes required to be imposed by local law in relation to
the provision of the Services.

 

		(c)	Sponsor will pay all invoices (including Upfront Payments) within 30 days of the date of the invoice.

 

Investigator Fees

 

		(a)	If Novotech will be paying sites and investigators on behalf of Sponsor (as set
out in any clinical trial agreement pursuant to the Services) (Investigator Fees) then upon receiving funds from Sponsor, Novotech
will agree a payment method with the Sponsor for payment of Investigator Fees in advance so that sites and investigators are paid for
their services in a timely manner.

 

		2.2	The agreed payment method is as follows:

 

On a quarterly basis, Novotech will:

 

		(b)	provide Sponsor with an invoice reflecting an estimate of the funding required
not later than 60 days prior to the start of a quarter to be paid by Sponsor within 30 days;

 

		(c)	submit a request to Sponsor with appropriate documentation as soon as practicable
if additional funds are required;

 

		(d)	adjust the forecast for the following quarter if not all funds are projected to be
disbursed by the end of a given quarter; and

 

		(e)	provide Sponsor with an accounting of funds disbursed to sites and investigators
and return excess funds promptly upon request of Sponsor or, 30 days after completion of the Services.

 

Upfront payments

 

		2.3	Each Appendix will provide that, upon commencement of the Services
in the Appendix, the Sponsor will pay a percentage of the total budgeted Professional Fees and Pass-Through Costs (together, Upfront
Payment). This upfront payment will be invoiced by Novotech as a security deposit and held on behalf of the Sponsor throughout the
period of the Study.

 

		2.4	The agreed Upfront Payment is 15% of the Total
                                                                                                                                                                                                                    Professional Fees and Pass through costs combined.

  

		2.5	Pass Through Costs

 

All pass through costs are fixed and
are included in the budget below. Novotech will include a flat fee of 5% of all invoiced Professional Fees to cover general phone, printing,
and other administrative expenses and Sponsor agrees to pay those fees.

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 12 of 21

     

    

 

Change in Scope Log

 

		2.6	As set out in Section 4 of the MSA, the parties have agreed
to use an informal change in scope process whereby an authorised representative of the Sponsor may approve additional or amended services
up to an agreed threshold value by email via the process set out below (such that a Change Order will not be required).

 

		2.7	If additional services are requested by the Sponsor that result in a change in
scope or budget increase of less than or equal to $5,000 (Agreed Change Value):

 

		(a)	Novotech will prepare a form showing all additional or amended services and a
cost estimate of those additional or amended services (Change in Scope Log) for approval by Sponsor;

 

		(b)	Sponsor will advise their authorized representative who is authorized to approve
the Change in Scope Log via email;

 

		(c)	Upon approval by an authorized person of the Sponsor, the additional or amended
services in the Change in Scope Log is agreed as binding on the parties such that Novotech is authorized by the Sponsor to commence those
services and Sponsor agrees to be responsible and liable for the costs associated with the additional or amended services;

 

		(d)	The additional or amended services in the Change in Scope Log will be incorporated
into a Change Order to the Appendix as and when Change in Scope Logs reach the Agreed Change Value, or, the Services are completed or
the Agreement terminates for any reason.

 

		2.8	The Parties agree to negotiate any proposed Change in Scope Log expeditiously and
in good faith so as not to impact the progress of the Services or cause administrative burden to either Party.

 

		2.9	Early Termination of the Services

 

By way of amendment to Section 8
of the Master Services Agreement between Sponsor and Novotech dated 25-Jun-2020, if the Study or this Appendix is terminated before all
Services have been performed, the parties agree that they will review fees incurred for services performed to the date of termination
and Sponsor will pay Novotech for any additional fees incurred to the date of termination as well as any pass through costs owing as at
the date of termination and any non-cancellable costs.

 

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 13 of 21

     

    

 

Executed as an Agreement

 

	Signed for and on behalf of
 Novotech (Australia) Pty Limited

                                                                                by
its authorised representative:
	 	Signed
for and behalf of

Incannex Healthcare Ltd

by its authorised representative:
	 	 	 
	Signature	 	Signature
	
     

     

     

     

    Name (print)
	 	
     

     

     

     

    Name (print)

	 	 	 
	Title	 	Title
	 	 	 
	Date:	 	Date:

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 14 of 21

     

    

 

 

 

 

Schedule 1Services Budget

 

 

 

Services

 

The parties agree that Novotech will provide the following
services to the Sponsor (Services) for the Professional Fees and Pass Through Costs below.

 

Scope of Work and Budget

 

This section details the activities
and tasks that will be carried out by Novotech as based upon Assumptions. Any desired amendments to the following section may necessitate
Novotech resubmitting an amended financial, and possibly timeline, proposal. A budget has been carefully prepared to ensure that Novotech
provides contract services at a cost that is deemed competitive and appropriate. Novotech develops its budgets on a unit cost basis with
certain activities being timesheet cost due to the variability of such tasks. All budgets are quoted in Australian Dollars (A$).

 

	Budget Summary:	Overall Budget (A$)
	Medical Writing	[***]
	Clinical	[***]
	Pharmacovigilance	[***]
	Data Management	[***]
	Biostatistics	[***]
	Total Novotech Budget	[***]

 

Reference:

As Inc: As Incurred, PT: Pass Through, X:
Responsible, R: Review

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 15 of 21

     

    

 

Detailed Medical Writing Budget

 

	Task	CLIENT	CRO	# of

Units	Base Unit 

Cost	Unit Type	Total

 Labour 

Cost
	CD) CLINICAL STUDY REPORT	 	 	 	 	 	 
	CSR Shell	R	[***]	[***]	[***]	[***]	[***]
	CSR Data Review Presentation Meeting	R	[***]	[***]	[***]	[***]	[***]
	CSR to 1st Draft CSR	R	[***]	[***]	[***]	[***]	[***]
	CSR to 2nd Draft CSR	R	[***]	[***]	[***]	[***]	[***]
	CSR Finalisation	R	[***]	[***]	[***]	[***]	[***]
	Changes/Updates to Final CSR	R	[***]	[***]	[***]	[***]	[***]
	TOTAL
    LABOUR	 	[***]	[***]	[***]	[***]	[***]
	General
    Admin Fee (5% Labour Costs)	 	[***]	[***]	[***]	[***]	[***]
	GRAND
    TOTAL	 	[***]	[***]	[***]	[***]	[***]

 

Detailed Clinical Budget

 

	Task	CLIENT	CRO	# of Units	PT Units	Base Unit

 Cost	Unit Type	PT 

Unit Cost	PT 

Unit Type	Total

 Labour Cost	Total PT

 Cost	Grand

 Total
	A) STUDY SET-UP	 	 	 	 	 	 	 	 	 	 	 
	STUDY DESIGN	 	 	 	 	 	 	 	 	 	 	 
	STUDY PLANNING & INITIATION	 	 	 	 	 	 	 	 	 	 	 
	Project Kick-Off & Familiarisation	x	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	Medical Monitors Kick Off Call	 	 	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	Project Management (Planning & Initiation)	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	PROJECT TEAM COMMUNICATION	 	 	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	
    Sponsor Teleconferences
	
    x
	
    x
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 16 of 21

     

    

 

	Internal Teleconferences/Meetings	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	PHARMACY & SUPPLY SET-UP	 	 	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	Pharmacy Manual Development	x	R	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	CLINICAL SET-UP	 	 	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	CRA Administration	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	PA & TMF Set-up Administration	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	CTMS Protocol Set-up	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	CTMS Site Set-up	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	CTMS Hosting (Start-up)	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	TMF Management Plan	R	R	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	EDC Training & User Acceptance Testing	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	Development of Site Initiation Material	R	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	Site Initiation Prep, Visit, Report & F-Up	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	TOTAL
    SECTION A)	 	 	 	 	 	 	 	 	[***]	[***]	[***]
	B) STUDY EXECUTION	 	 	 	 	 	 	 	 	 	 	 
	STUDY MANAGEMENT	 	 	 	 	 	 	 	 	 	 	 
	Project Management (Enrolment & Treatment)	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	PROJECT TEAM COMMUNICATION	 	 	 	 	 	 	 	 	 	 	 
	Sponsor Teleconferences	x	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	Internal Teleconferences/Meetings	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	CLINICAL MONITORING/SITE MANAGEMENT	 	 	 	 	 	 	 	 	 	 	 
	Monitoring Visit (Days on-Site)	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	Travel Per Visit	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	Prep, Report, Follow Up	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 17 of 21

     

    

 

	Monitoring Visit Report Review/Approval	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	CRA Administration (Enrolment & Treatment)	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	CTMS Hosting (Enrolment, Treatment & Maintenance)	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	PA Admin & TMF Management (Enrolment & Treatment)	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	SAFETY REPORTING	 	 	[***]	 	 	 	 	 	 	 	 
	Local Medical Monitoring (Enrolment & Treatment)	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	SAE Reporting - Timesheet	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	TOTAL
    SECTION B)	 	 	 	 	 	 	 	 	[***]	[***]	[***]
	C) STUDY CLOSE-OUT	 	 	 	 	 	 	 	 	 	 	 
	STUDY MANAGEMENT & MONITORING	 	 	 	 	 	 	 	 	 	 	 
	Project Management (Close-out)	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	Close-Out Visits Prep, Visit, Report & F-up	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	CRA Administration (Close-out)	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	PA & TMF Administration (Close-out)	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	CTMS Hosting (Close-out)	 	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	Local Medical Monitor - End of Study Review	 	 	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	Return of Deliverables to Sponsor	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	PROJECT COMMUNICATION	 	 	 	 	 	 	 	 	 	 	 
	Sponsor Teleconferences	x	x	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	Internal Teleconferences/Meetings	 	x	[***]	 	[***]	[***]	 	 	[***]	 	[***]
	TOTAL
    SECTION C)	 	 	 	 	 	 	 	 	[***]	[***]	[***]
	TOTAL	 	 	 	 	 	 	 	 	[***]	[***]	[***]
	General
    Admin Fee (5% Labour Costs)	 	 	 	 	 	 	 	 	[***]	[***]	[***]
	GRAND
    TOTAL	 	 	 	 	 	 	 	 	[***]	[***]	[***]

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 18 of 21

     

    

 

Detailed Pharmacovigilance Budget

 

	Task	Unit Type	Base Unit Cost	# of units	Grand Total
	Safety Monitoring Set-Up and Start-Up	Per Database	[***]	[***]	[***]
	SAE Management (Ex. Safety Narratives) - Initial	Per SAE report (initial)	[***]	[***]	[***]
	SAE Management (Ex. Safety Narratives) - Follow Up	Per SAE report (follow-up)	[***]	[***]	[***]
	Safety Narratives for Non-expedited Report	Per SAE report	[***]	[***]	[***]
	SUSAR Management (Includes Narratives/CIOMS Generation)	Per SUSAR report	[***]	[***]	[***]
	SUSAR Reporting (Investigator Submission)	Per SUSAR	[***]	[***]	[***]
	DSUR - Exectuive Summary Preparation	Per Year	[***]	[***]	[***]
	Generate Monthly Safety Status Report	Per Month (Ex. Start-up)	[***]	[***]	[***]
	Safety database transfer - study end	Per Report	[***]	[***]	[***]
	Safety Management Plan	Per Study	[***]	[***]	[***]
	Submit SUSAR to RA	Per SUSAR Report	[***]	[***]	[***]
	TOTAL	 	 	 	[***]
	General
    Admin Fee (5% Labour Costs)	 	 	 	[***]
	GRAND
    TOTAL	 	 	 	[***]

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 19 of 21

     

    

 

Detailed Data Management Budget

 

	Task	CLIENT	CRO	# of Units	Base Unit

Cost	Unit Type	Total 

Labour

Cost
	STUDY SETUP	 	 	 	 	 	 
	eCRF DATABASE DEVELOPMENT	 	 	 	 	 	 
	eCRF: Screens Design and Database Build	R	x	[***]	[***]	[***]	[***]
	eCRF: Screens and Database Review	R	x	[***]	[***]	[***]	[***]
	Edit Checks	R	x	[***]	[***]	[***]	[***]
	User Acceptance Testing	R	x	[***]	[***]	[***]	[***]
	EDC Vendor Services Fee (Professional Services Fees)	 	x	[***]	[***]	[***]	[***]
	EDC Vendor Service Fee (Monthly Licensing Fee)	 	x	[***]	[***]	[***]	[***]
	Database Release to Production	 	x	[***]	[***]	[***]	[***]
	DATA MANAGEMENT TOOLS	 	 	 	 	 	 
	eCRF Completion Guidelines	 	x	[***]	[***]	[***]	[***]
	Importable Laboratory Data (eg. PK, Pathology)	 	x	[***]	[***]	[***]	[***]
	Data Management Plan	R	x	[***]	[***]	[***]	[***]
	Data Review Plan	 	x	[***]	[***]	[***]	[***]
	Data Review Programs Development	 	x	[***]	[***]	[***]	[***]
	Data Review Program External Listings	 	x	[***]	[***]	[***]	[***]
	STUDY EXECUTION	 	 	 	 	 	 
	DATA REVIEW & VALIDATION	 	 	 	 	 	 
	Data Cleaning	 	x	[***]	[***]	[***]	[***]
	Data Review & Reconciliation of External Data	 	 	[***]	[***]	[***]	[***]
	Project Administration and Maintenance	 	x	[***]	[***]	[***]	[***]
	Data Processing Report	 	x	[***]	[***]	[***]	[***]
	eCRF User Profiles Administration and Maintenance	 	x	[***]	[***]	[***]	[***]
	eCRF/Database Administration	 	x	[***]	[***]	[***]	[***]
	Coding of Medical Verbatim Terms	 	x	[***]	[***]	[***]	[***]
	Medical Review of Coded Medical Verbatim Terms	 	x	[***]	[***]	[***]	[***]
	Reconciliation of SAE Data in eCRF and Safety Database	 	x	[***]	[***]	[***]	[***]
	DATABASE LOCK & COMPLETION (HARD LOCK)	 	 	 	 	 	 
	Database QA	 	x	[***]	[***]	[***]	[***]
	Database Lock (Hard Lock)	 	x	[***]	[***]	[***]	[***]
	AD HOC TASKS	 	 	 	 	 	 
	 Ad hoc Tasks	 	x	T	[***]	[***]	[***]
	STUDY CLOSE OUT	 	 	 	 	 	 
	DECOMMISIONING AND ARCHIVING	 	 	 	 	 	 
	eCRF/Database Decommissioning	 	x	[***]	[***]	Subjects	[***]
	Database Closeout Administration	 	x	[***]	[***]	Study	[***]
	Archiving (TMF Database Management)	 	x	[***]	[***]	Study	[***]
	TOTAL	 	 	 	 	 	[***]
	General
    Admin Fee (5% Labour Costs)	 	 	 	 	 	[***]
	GRAND
    TOTAL	 	 	 	 	 	[***]

 

    	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 20 of 21

     

    

 

Detailed Biostatistics Budget

 

	Task	CLIENT	CRO	# of Units	Base Unit

Cost	Unit Type	Total

Labour

Cost
	STUDY EXECUTION	 	 	 	 	 	 
	STUDY ADMINISTRATION	 	 	 	 	 	 
	Project Administration and Maintenance	 	x	[***]	[***]	Months	[***]
	STATISTICAL ANALYSIS PLAN	 	 	 	 	 	 
	SAP creation	 	x	[***]	[***]	Plan	[***]
	TFL Shell Creation	 	x	[***]	[***]	TFLs	[***]
	Incorporation of Sponsor Comments	 	x	[***]	[***]	Reviews	[***]
	SAP Update Required	 	x	[***]	[***]	Plan	[***]
	SAP Finalisation	 	x	[***]	[***]	Plan	[***]
	TFL Shell Finalisation	 	x	[***]	[***]	Plan	[***]
	FINAL TFLs	 	 	 	 	 	 
	Unique TFLs	 	x	 	 	 	 
	Tables (Unique) Programming	 	 	[***]	[***]	Final (EOS) Unique Tables	[***]
	Listings (Unique) Programming	 	 	[***]	[***]	Final (EOS) Unique Listings	[***]
	Figures (Unique) Programming	 	 	[***]	[***]	Final (EOS) Unique Figures	[***]
	Repeat TFLs	 	x	 	 	 	 
	Tables (Repeat) Programming	 	 	[***]	[***]	Final (EOS) Repeat Tables	[***]
	Listings (Repeat) Programming	 	 	[***]	[***]	Final (EOS) Repeat Listings	[***]
	QC of TFLs	R	x	 	 	 	 
	QC Unique TFLs	 	 	[***]	[***]	Final Unique TFLs	[***]
	QC Repeat TFLs	 	 	[***]	[***]	Final Repeat TFLs	[***]
	PD ANALYSIS	 	 	 	 	 	 
	PD Analysis	 	x	[***]	[***]	Analytes	[***]
	AD HOC TASKS	 	 	 	 	 	 
	Ad
hoc Tasks	 	x	T	TIMESHEET	TIMESHEET	TIMESHEET
	CDISC DATASET SUBMISSION PACKAGE	 	 	 	 	 	 
	SDTM Submission Package	 	x	[***]	[***]	SDTM Domains	[***]
	ADaM Submission Package	 	x	[***]	[***]	ADaM Domains	[***]
	STUDY CLOSE OUT	 	 	 	 	 	[***]
	CLOSE OUT ADMINISTRATION	 	 	 	 	 	[***]
	Archiving	 	x	[***]	[***]	Report	[***]
	TOTAL	 	 	 	 	 	[***]
	General
    Admin Fee (5% Labour Costs)	 	 	 	 	 	[***]
	GRAND
    TOTAL	 	 	 	 	 	[***]

 

	Project Agreement – Early Phase services	Version 2 – August 2020
	Incannex Healthcare Ltd, IHLOSAOLE1, Novotech no. 2020-9302	Page 21 of 21EX-10.1

 Exhibit 10.1 
  

	
	 PHATHOM PHARMACEUTICALS, INC.

 
 2019 INCENTIVE AWARD PLAN

 

 RESTRICTED STOCK UNIT GRANT NOTICE 

Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the
meanings given to them in the 2019 Incentive Award Plan (as amended from time to time, the “Plan”) of Phathom Pharmaceuticals, Inc. (the “Company”). 

The Company hereby grants to the participant listed below (“Participant”) the Restricted Stock Units described in this
Grant Notice (the “RSUs”), subject to the terms and conditions of the Plan and the Restricted Stock Unit Agreement attached hereto as Exhibit A (the “Agreement”), both of which are incorporated
into this Grant Notice by reference. 
  

			
	Participant:	  	[Insert Participant Name]
		
	Grant Date:	  	[Insert Grant Date]
		
	Number of RSUs:	  	[Insert Number of RSUs]
		
	Vesting Commencement Date:	  	[Insert Vesting Commencement Date]
		
	Vesting Schedule:	  	Subject to the Participant’s continued service, one-third (1/3rd) of the RSUs shall vest on each of the first, second and third
anniversaries of the Vesting Commencement Date.

 By electronically accepting this document, Participant agrees to be bound by the terms of this Grant
Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all
provisions of the Plan, this Grant Notice and the Agreement. Participant has been provided with a copy or electronic access to a copy of the prospectus for the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions
or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. 
  

									
	PHATHOM PHARMACEUTICALS, INC.	 		 	PARTICIPANT
					
	By:	 	  
	 		 	By:	 	  

	Print Name:	 	  
	 		 	Print Name:	 	  

	Title:	 	  
	 		 		 	

 EXHIBIT A 

RESTRICTED STOCK UNIT AGREEMENT 

Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant
Notice, in the Plan. 
 ARTICLE I. 

GENERAL 
 1.1 Award of
RSUs. The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the “Grant Date”). Each RSU represents the right to receive one Share, as set forth in this Agreement.
Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested. 
 1.2 Incorporation of
Terms of Plan. The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan
will control. 
 1.3 Unsecured Promise. The RSUs will at all times prior to settlement represent an unsecured Company obligation
payable only from the Company’s general assets. 
 ARTICLE II. 

VESTING; FORFEITURE AND SETTLEMENT 

2.1 Vesting; Forfeiture. The RSUs will vest according to the vesting schedule in the Grant Notice (the “Vesting
Schedule”), except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. In the event of Participant’s Termination of Service for any reason, all
unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company. Unless and until the RSUs have vested in
accordance with the Vesting Schedule set forth in the Grant Notice, Participant will have no right to any distribution with respect to such RSUs. 

2.2 Settlement. 
 (a)
RSUs will be paid in Shares as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than sixty (60) days after the applicable vesting date. Notwithstanding the foregoing, the Company may delay any
payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury
Regulation Section 1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A. 

(b) All distributions shall be made by the Company in the form of whole shares of Common Stock. 

(c) Neither the time nor form of distribution of Shares with respect to the RSUs may be changed, except as may be permitted by the
Administrator in accordance with the Plan and Section 409A of the Code and the Treasury Regulations thereunder. 

  
 A-1 

 ARTICLE III. 

TAXATION AND TAX WITHHOLDING 

3.1 Representation. Participant represents to the Company that Participant has reviewed with Participant’s own tax advisors the
tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. 

3.2 Tax Withholding. 

(a) The Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the RSUs to Participant or his
or her legal representative unless and until Participant or his or her legal representative shall have paid or otherwise satisfied in full the amount of all federal, state, local and foreign taxes applicable with respect to the taxable income of
Participant resulting from the vesting or settlement of the RSUs, the distribution of the Shares issuable with respect thereto, or any other taxable event related to the RSUs (the “Tax Withholding Obligation”). 

(b) Participant may elect to satisfy the Tax Withholding Obligation as provided in Section 9.5 of the Plan. Unless Participant elects to
satisfy the Tax Withholding Obligation by one of the means described in Section 9.5 of the Plan, the Company has the right and option, but not the obligation, to treat Participant’s failure to provide timely payment in accordance with the
Plan of any withholding tax arising in connection with the RSUs as Participant’s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Award. 

(a) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs, regardless
of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the RSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any
tax withholding in connection with the awarding, vesting or payment of the RSUs or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the RSUs to reduce or eliminate
Participant’s tax liability. 
 ARTICLE IV. 

OTHER PROVISIONS 
 4.1
Award Not Transferable. Without limiting the generality of any other provision hereof, the Award shall be subject to the restrictions on transferability set forth in Section 9.1 of the Plan. 

4.2 Adjustments. Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and
termination in certain events as provided in this Agreement and the Plan. 
 4.3 Notices. Any notice to be given under the terms of
this Agreement to the Company must be in writing and addressed to the Company in care of the Company’s Secretary at the Company’s principal office or the Secretary’s then-current email address or facsimile number. Any notice to be
given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the Designated Beneficiary) at Participant’s last known mailing address, email address or facsimile
number in the Company’s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by
email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express
shipping company or upon receipt of a facsimile transmission confirmation. 

  
 A-2 

 4.4 Titles. Titles are provided herein for convenience only and are not to serve as a
basis for interpretation or construction of this Agreement. 
 4.5 Conformity to Securities Laws. Participant acknowledges that the
Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws. 

4.6 Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this
Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in this Agreement or the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees,
legal representatives, successors and assigns of the parties hereto. 
 4.7 Limitations Applicable to Section 16
Persons. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the RSUs will be subject to any additional limitations
set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule. To the extent
Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. 
 4.8 Entire
Agreement. The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with
respect to the subject matter hereof. 
 4.9 Agreement Severable. In the event that any provision of the Grant Notice or this
Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. 

4.10 Limitation on Participant’s Rights. Participation in the Plan confers no rights or interests other than as herein provided.
This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have
only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with
respect to the RSUs, as and when settled pursuant to the terms of this Agreement. 
 4.11 Not a Contract of Employment. Nothing in
the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which
rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or
a Subsidiary and Participant. 
 4.12 Counterparts. The Grant Notice may be executed in one or more counterparts, including by way of
any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. 

  
 A-3 

 4.12 Section 409A. 

(a) Notwithstanding any other provision of the Plan, this Agreement or the Grant Notice, the Plan, this Agreement and the Grant Notice shall
be interpreted in accordance with, and incorporate the terms and conditions required by, Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without
limitation any such regulations or other guidance that may be issued after the Grant Date, “Section 409A”). The Administrator may, in its discretion, adopt such amendments to the Plan, this Agreement or the Grant Notice or adopt other
policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate to comply with the requirements of Section 409A. 

(b) This Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly,
the Shares issuable pursuant to the RSUs hereunder shall be distributed to Participant no later than the later of: (A) the fifteenth (15th) day of the third month following Participant’s first taxable year in which such RSUs are no longer
subject to a substantial risk of forfeiture, and (B) the fifteenth (15th) day of the third month following first taxable year of the Company in which such RSUs are no longer subject to substantial risk of forfeiture, as determined in accordance
with Section 409A and any Treasury Regulations and other guidance issued thereunder. 
 4.13 Governing Law. The provisions of
the Plan and all Awards made thereunder, including the RSUs, shall be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding
choice-of-law principles of the law of any state that would require the application of the laws of a jurisdiction other than such state. 

* * * * * 

  
 A-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]